

FIG.1 REACTIVITY OF ANTI-FACTOR D MABs WITH FACTOR D IN ELISA




FIG.2

INHIBITION OF AP HEMOLYSIS BY ANTI-FACTOR D ANTIBODY 166-32




FIG. 3

INHIBITION OF ALTERNATIVE PATHWAY HEMOLYSIS  
BY MAb 166-32 IN 90% HUMAN SERUM




Figure 4 shows the effect of anti-factor D mAb 166-32 on CP hemolysis. The data indicates that mAb 166-32 inhibits CP hemolysis in a dose-dependent manner, with higher concentrations leading to greater inhibition.

FIG.4

EFFECT OF ANTI-FACTOR D MAb 166-32 ON CP HEMOLYSIS




FIG.5 INHIBITION OF FACTOR D DEPENDENT AP HEMOLYSIS BY MAb 166-32




FIG.6

EFFECT OF ANTI-FACTOR D MAb 166-32 ON  
FACTOR D DEPENDENT EAC3b CELL LYSIS




FIG.7

EFFECT OF MAb 166-32 ON C3 $\alpha$  PRODUCTION  
VIA AP COMPLEMENT ACTIVATION ON ZYMOSAN




FIG. 8






FIG.9

INHIBITION OF AP HEMOLYSIS BY ANTI-FACTOR D  
ANTIBODY 166-32 AND ITS Fab FRAGMENT





FIG. 10



EPITOPE MAPPING OF MAb 166-32 USING BACULOVIRUS-EXPRESSED FACTOR D MUTANTS




FIG. 12

SCHEMATIC REPRESENTATION OF THE EXPRESSION VECTOR PLASMIDS FOR CHIMERIC 166-32 Fab: (A) pSV2dhfrFd AND (B) pSV2neoK





FIG.13

INHIBITION OF AP HEMOLYSIS BY ANTI-FACTOR D  
ANTIBODY 166-32 AND ITS CHIMERIC FORM



**FIG. 14** INHIBITION OF AP HEMOLYSIS BY CHIMERIC 166-32 IgG AND ITS Fab




FIG.15  
 EFFECTS OF MAb 166-32 ON LVEDP AND LVDP  
 OF ISOLATED RABBIT HEARTS PERFUSED WITH HUMAN PLASMA




FIG. 16

EFFECT OF 4% HUMAN PLASMA ON VENTRICULAR  
CONTRACTILE FUNCTION : RABBIT ISOLATED HEART






FIG. 17

EFFECTS OF MAb 166-32 ON THE LEVELS OF  
Bb IN CARDIAC LYMPH OF ISOLATED  
RABBIT HEARTS PERFUSED WITH HUMAN PLASMA




FIG. 18

ALTERNATIVE PATHWAY HEMOLYTIC ACTIVITY OF  
PLASMA FROM EXTRACORPOREAL CIRCUITS




FIG. 19 C3a PRODUCTION IN EXTRACORPOREAL CIRCUITS




FIG. 20

sC5b-9 PRODUCTION IN EXTRACORPOREAL CIRCUITS




FIG.21

Bb PRODUCTION IN EXTRACORPOREAL CIRCUITS




FIG. 22 C4d PRODUCTION IN EXTRACORPOREAL CIRCUITS




FIG. 23

FIG. 23

CD11b EXPRESSION ON NEUTROPHILS IN EXTRACORPOREAL CIRCUITS




FIG.24






FIG.25

MYELOPEROXIDASE LEVEL IN EXTRACORPOREAL CIRCUITS





Fig. 26 Selective inhibition of the alternative complement pathway  
by anti-factor D MAb 166-32



Bb concentration (µg/ml)




Fig. 27 Bb production in extracorporeal circuits

Fig. 28 C4d production in extracorporeal circuits




Fig. 29 C3a production in extracorporeal circuits




Fig. 30 sC5b-9 production in extracorporeal circuits




Fig. 31 C5a production in extracorporeal circuits




Fig. 32 CD11b expression on neutrophils in extracorporeal circuits






Figure 33 shows the myeloperoxidase production in extracorporeal circuits. The graph plots MPO concentration (ng/ml) on the y-axis against Time (Min) on the x-axis. Two circuits are compared: Mab 166-32 (filled squares) and Negative control Mab (open squares). Both circuits show an increase in MPO concentration over time. The Mab 166-32 circuit shows a significantly higher MPO concentration than the Negative control Mab circuit at 80, 120, and 160 minutes, as indicated by the asterisks (\* and \*\*).

Fig. 33 Myeloperoxidase production in extracorporeal circuits




Fig. 34 Elastase- $\alpha$ 1-antitrypsin production in extracorporeal circuits

Fig. 34 Elastase- $\alpha$ 1-antitrypsin production in extracorporeal circuits




Fig. 35 CD62P expression on platelets in extracorporeal circuits




Fig. 36 CD62P-positive platelets in extracorporeal circuits




Fig. 37 Platelet thrombospondin production in extracorporeal circuits






Fig. 38 IL-8 production in extracorporeal circuits




**Fig. 39 Pharmacokinetics of MAb166-32 in Baboon CPB**

(5 mg/kg MAb166-32, single iv. bolus)




**Fig. 40 Inhibition of Alternative Complement  
by MAb166-32 in Baboon CPB**







# Fig. 41 Bb in Baboon CPB




**Fig. 42 C4d in Baboon CPB**




**Fig. 43 C3a in Baboon CPB**




**Fig. 44 CD11b Expression on Neutrophils in Baboon CPB**




**Fig.45 CD11b Expression on Monocytes in Baboon CPB**




**Fig. 4b CD62P Expression on Platelets in Baboon CPB**



**Fig. 47 Plasma IL-6 in Baboon CPB**




**Fig. 48 Plasma LDH Level in Baboon CPB**






**Fig. 49 Plasma Creatine Kinase (CK) Level in Baboon CPB**




**Fig. 50 Plasma Creatine Kinase Isozymes (CK-MB) in Baboon CPB**



**Fig. 51 Plasma Creatinine Level in Baboon CPB**

(18 hr post-CPB,  $p=0.01$ )



**Fig. 52 Dynamic Lung Compliance of Baboons in CPB**

